Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 2/20 | 0.32 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801881 | 0.98 | ZDHHC20 (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL6390028 | 0.89 | ZDHHC20 (0.56) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL22556976 | 0.87 | ZDHHC20 (0.58) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL17414844 | 0.85 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL475906 | 0.83 | ZDHHC20 (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL3764640 | 0.83 | ZDHHC20 (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL137143 | 0.82 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Bromide SCHEMBL6117271 | 0.81 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL1200572 | 0.81 | ZDHHC20 (0.53) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL3133989 | 0.80 | ZDHHC20 (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111428-A1 | METHOD FOR PRODUCTION OF VINYL CARBOXAMIDE CONTAINING POLYMERS IN PARTICULATE FORM | SOLENIS TECHNOLOGIES CAYMAN, L.P. (CH) | 2025-05-30 | — | — | WO | disclosed |
| US-20250163194-A1 | METHOD OF PRODUCING VINYLAMINE-CONTAINING POLYMERS | SOLENIS TECHNOLOGIES, L.P. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250163190-A1 | METHODS OF FORMING CATIONIC POLYMERS USING INITIATORS ACTIVATED ONLY BY ULTRAVIOLET LIGHT | SOLENIS TECHNOLOGIES, L.P. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250163647-A1 | METHOD FOR PRODUCTION OF VINYL CARBOXAMIDE CONTAINING POLYMERS IN PARTICULATE FORM | SOLENIS TECHNOLOGIES, L.P. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250163646-A1 | PARTICULATE VINYLAMINE COMPOSITIONS AND METHOD OF MAKING | SOLENIS TECHNOLOGIES, L.P. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12018113-B2 | Method for the hydrolysis of a polymer | SOLENIS TECHNOLOGIES, L.P. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3695051-B1 | METHOD FOR FORMING PAPER OR CARDBOARD | SOLENIS TECHNOLOGIES CAYMAN LP (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-115162044-B | Method for producing paper or board | 索理思科技开曼公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3965722-B1 | TOPICAL COMPOSITIONS WITH PRESERVATIVE SYSTEM | DSM IP ASSETS BV (NL) | 2023-08-16 | — | — | EP | disclosed |
| EP-3965721-B1 | TOPICAL COMPOSITIONS WITH ANTIMICROBIAL AGENT MIXTURE | DSM IP ASSETS BV (NL) | 2023-06-14 | — | — | EP | disclosed |
| EP-1509220-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4- 2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO 2,5]OCTAN-6-ONE | Mycoplus Co., Ltd. (KR) | 2005-03-02 | — | — | EP | disclosed |
| US-20040039030-A1 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | HOECHST AKEENGESELLSCHAFT (DE) | 2004-02-26 | — | — | US | disclosed |
| US-6663875-B2 | Mixture containing oxiconazole nitrate | CLARIANT GMBH (DE) | 2003-12-16 | — | — | US | disclosed |
| WO-2003094908-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHEA CONTAINING 4-HYDROXY-5-METHOXY-4-[2-METHYL-3(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1-OXASPIRO[2,5]OCTAN-6-ONE | MYCOPLUS CO., LTD. (KR) | 2003-11-20 | — | — | WO | disclosed |
| US-20030049292-A1 | Hair treatments comprising zinc salts of piroctone olamine | CLARIANT GMBH | 2003-03-13 | — | — | US | disclosed |
| US-20030044375-A1 | Hair preparation for the treatment of dandruff | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| US-20020061827-A1 | Aqueous liquids comprising a surfactant and an acetal | CLARIANT GMBH | 2002-05-23 | — | — | US | disclosed |
| US-20020037299-A1 | Cosmetic compositions comprising zinc salts of piroctone olamine | CLARIANT GMBH | 2002-03-28 | — | — | US | disclosed |
| US-5494658-A | CONTAINING A BENZENE AND A 1,2-DIHYDROPYRID-1-OL-2-ONE RINGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-27 | — | — | US | disclosed |
| US-4472421-A | SHAMPOO | BAYER AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039030-A1 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | CYP24A1, CYP27B1, HSD3B1 | ACHE 3462/4885ZDHHC20 1157/4885ZDHHC2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.